课题基金 / 基金详情

项目摘要

项目成果

Deborah Merke的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究仅限于21-羟化酶缺乏症导致的典型先天性肾上腺增生患者,但有可能显著改善其他形式肾上腺功能不全患者的生活。每一种疾病都需要终身治疗,这种新的给药方法有可能显著改善患者的生活。该试点研究已全部纳入,仅处于随访状态,数据分析正在进行中。此外,本研究将提供关于使用泵输送氢化可的松的安全性和耐受性的信息,并将产生将用于未来研究设计的数据。
英文摘要
This study is limited to patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, but has the potential to significantly improve the lives of patients with other forms of adrenal insufficiency. Each of these diseases requires life-long treatment and this novel approach to drug delivery has the potential to significantly improve patients lives. This pilot study is fully enrolled and is in follow-up only status and data analysis is underway. In addition, this study will provide information on the safety and tolerability of using a pump to deliver hydrocortisone, and will generate data that will be used in the design of future studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modified-release Hydrocortisone Therapy as a Treatment for CAH
Novel treatment approaches: sex steroid blockade in children
  • 批准号:
    10916862
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位:
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
  • 批准号:
    10252568
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位:
海外基金